Trial Profile
An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs WP 1303 Worg Pharmaceuticals (Primary)
- Indications Multiple sclerosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Merck KGaA
- 12 Feb 2018 Primary endpoint (Change From Baseline in the Average Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) Over On-treatment Scans) has been met as per the results published in the Neurology.
- 12 Feb 2018 Results published in the Neurology
- 21 Feb 2017 Results published in an Apitope Technology media release